down arrow

BrightGene Bio-Medical Technology Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003PR1
  • SHG: 688166
CNY
36.30
-0.51 (-1.39%)

Sep 23

SHG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
BrightGene Bio-Medical Technology Co., Ltd.

Why is BrightGene Bio-Medical Technology Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 7.70%
  • The company has been able to generate a Return on Capital Employed (avg) of 7.70% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of 9.01% and Operating profit at -23.73% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 9.15% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 9.01% and Operating profit at -23.73% over the last 5 years
4
The company has declared positive results in Jun'2026 after 10 consecutive negative quarters
  • INTEREST COVERAGE RATIO(Q) Highest at 583.13
  • RAW MATERIAL COST(Y) Fallen by -5.13% (YoY)
  • CASH AND EQV(HY) Highest at CNY 2,737.68 MM
5
With ROE of 1.44%, it has a very expensive valuation with a 5.92 Price to Book Value
  • Over the past year, while the stock has generated a return of -55.00%, its profits have fallen by -52.5%
  • At the current price, the company has a high dividend yield of 0
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to BrightGene Bio-Medical Technology Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is BrightGene Bio-Medical Technology Co., Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
BrightGene Bio-Medical Technology Co., Ltd.
-50.96%
0.10
64.66%
China Shanghai Composite
3.0%
0.22
14.72%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
9.01%
EBIT Growth (5y)
-23.73%
EBIT to Interest (avg)
5.95
Debt to EBITDA (avg)
5.17
Net Debt to Equity (avg)
0.57
Sales to Capital Employed (avg)
0.25
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
12.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.27%
ROE (avg)
9.15%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
411
Industry P/E
Price to Book Value
5.92
EV to EBIT
321.61
EV to EBITDA
93.70
EV to Capital Employed
3.95
EV to Sales
12.82
PEG Ratio
NA
Dividend Yield
0.05%
ROCE (Latest)
1.23%
ROE (Latest)
1.44%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company
INTEREST COVERAGE RATIO(Q)

Highest at 583.13

RAW MATERIAL COST(Y)

Fallen by -5.13% (YoY

CASH AND EQV(HY)

Highest at CNY 2,737.68 MM

DEBT-EQUITY RATIO (HY)

Lowest at 41.12 %

INVENTORY TURNOVER RATIO(HY)

Highest at 1.91 times

DEBTORS TURNOVER RATIO(HY)

Highest at 3.51 times

NET SALES(Q)

Highest at CNY 353.16 MM

OPERATING PROFIT(Q)

Highest at CNY 117.02 MM

OPERATING PROFIT MARGIN(Q)

Highest at 33.13 %

PRE-TAX PROFIT(Q)

Highest at CNY 56.91 MM

NET PROFIT(Q)

Highest at CNY 35.6 MM

EPS(Q)

Highest at CNY 0.11

-9What is not working for the Company
INTEREST(Q)

Highest at CNY 20.07 MM

Here's what is working for BrightGene Bio-Medical Technology Co., Ltd.

Pre-Tax Profit
At CNY 56.91 MM has Grown at 1,044.86%
over average net sales of the previous four periods of CNY 4.97 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 35.6 MM has Grown at 293.48%
over average net sales of the previous four periods of CNY 9.05 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Interest Coverage Ratio
Highest at 583.13
in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales
Highest at CNY 353.16 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit
Highest at CNY 117.02 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin
Highest at 33.13 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit
Highest at CNY 56.91 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit
Highest at CNY 35.6 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS
Highest at CNY 0.11
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Cash and Eqv
Highest at CNY 2,737.68 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at 41.12 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Inventory Turnover Ratio
Highest at 1.91 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 3.51 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -5.13% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for BrightGene Bio-Medical Technology Co., Ltd.

Interest
Highest at CNY 20.07 MM
in the last five periods and Increased by 7.99% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Footer loading